Contrasting Halozyme Therapeutics (NASDAQ:HALO) & Soligenix (NASDAQ:SNGX)

Soligenix (NASDAQ:SNGX – Get Free Report) and Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Volatility & Risk

Soligenix has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Profitability

This table compares Soligenix and Halozyme Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Soligenix N/A -165.32% -97.40%
Halozyme Therapeutics 26.93% 751.81% 23.84%

Institutional and Insider Ownership

3.6% of Soligenix shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 1.9% of Soligenix shares are held by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Soligenix and Halozyme Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Soligenix N/A N/A -$11.08 million ($0.45) -0.71
Halozyme Therapeutics $1.40 billion 8.19 $316.89 million $3.93 25.51

Halozyme Therapeutics has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Soligenix and Halozyme Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soligenix 1 0 0 0 1.00
Halozyme Therapeutics 1 5 7 0 2.46

Halozyme Therapeutics has a consensus target price of $108.18, suggesting a potential upside of 7.89%. Given Halozyme Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Halozyme Therapeutics is more favorable than Soligenix.

Summary

Halozyme Therapeutics beats Soligenix on 12 of the 13 factors compared between the two stocks.

About Soligenix

(Get Free Report)

Soligenix, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare diseases and other serious medical conditions. Its work spans therapeutic programs for inflammatory and immunological disorders, as well as vaccine and medical countermeasure development. The company’s BioTherapeutics programs include HyBryte (SGX301), a topical treatment based on synthetic hypericin being developed for cutaneous T-cell lymphoma, and dusquetide (SGX942), which has been studied for oral mucositis associated with cancer treatment.

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.